ERBB2 and neoplasm: Most clinicians use grade of differentiation, age, tumor size, steroid hormone receptor status, HER2 expression and sometimes proliferation markers (e.g. Ki-67 or gene signatures like OncotypeDXTM) in order to decide which patient with node-negative disease should receive adjuvant chemotherapy.